ProfileGDS5678 / 1416271_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 50% 51% 51% 50% 49% 48% 67% 86% 50% 49% 51% 50% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2284749
GSM967853U87-EV human glioblastoma xenograft - Control 23.2045250
GSM967854U87-EV human glioblastoma xenograft - Control 33.2177751
GSM967855U87-EV human glioblastoma xenograft - Control 43.1574751
GSM967856U87-EV human glioblastoma xenograft - Control 53.1351750
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.258149
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.218148
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0902667
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5265986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1831450
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1724349
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1822351
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1993650
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.192950